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ABSTRACT
Inhibin B is produced by Sertoli cells, provides negative feedback
on FSH secretion, and may prove to be an important marker for the
functioning of seminiferous tubules. The purpose of the present study
was to examine the relationship between the spermatogenic function
of the testis of subfertile men and the plasma concentrations of inhibin
B and FSH. These parameters were estimated in a group of 218
subfertile men.
Serum inhibin B levels were closely correlated with the serum FSH
levels (r 5 20.78, P , 0.001), confirming the role of inhibin B as
feedback signal for FSH production.
The spermatogenic function of the testis was evaluated by deter-
mining testicular volume and total sperm count. Inhibin B levels were
significantly correlated with the total sperm count and testicular
volume (r 5 0.54 and r 5 0.63, respectively; P , 0.001).
Testicular biopsies were obtained in 22 of these men. Inhibin B was
significantly correlated with the biopsy score (r 5 0.76, P , 0.001).
Receiver operating characteristic analysis revealed a diagnostic ac-
curacy of 95% for differentiating competent from impaired spermat-
ogenesis for inhibin B, whereas for FSH, a value of 80% was found.
We conclude that inhibin B is the best available endocrine marker
of spermatogenesis in subfertile men. (J Clin Endocrinol Metab 83:
3110–3114, 1998)
FSH is currently regarded as the most important endo-crine parameter in the evaluation of male infertility (1).
Its secretion can be suppressed by the testicular hormone
inhibin, which is produced in Sertoli cells and may, therefore,
be a serum marker for Sertoli cell function. Attempts to
confirm this role of inhibin originally yielded contradictory
results. Results of heterologous inhibin assays demonstrated
that serum inhibin levels were stimulated with exogenous
FSH and decreased after treatment with GnRH antagonists,
radiotherapy-induced testicular damage, and testosterone
(2–6). In contrast, a negative correlation between inhibin and
FSH levels could not be shown, and inhibin levels in fertile
controls and subfertile men with testicular disorders were
not different (7).
This discrepancy can now be explained on the basis of the
aspecificity of the inhibin assay that was used. Inhibin is a
dimer of an a- and a b-subunit. Depending on the type of
b-subunit, (bA or bB), inhibin A or inhibin B is formed. The
antibodies used in the heterologous inhibin RIA were di-
rected against the a-subunit, and they detected both dimeric
inhibin and biologically inactive monomeric a-subunits (8).
Since new specific sandwich assays for inhibin A, inhibin B,
and uncombined a-subunits have been developed, studies
have been undertaken to investigate the role of inhibins in
male and female endocrinology.
One major finding is that inhibin B is the physiologically
important form of inhibin in the male, serum inhibin A levels
being undetectable (9). The finding that castration results in
undetectable inhibin B levels indicates that circulating in-
hibin B is produced by the testes (10). Furthermore, recent
papers have reported a strong negative correlation between
FSH and inhibin B in fertile and subfertile men (9, 11–14).
Little information is available on the correlation of inhibin
B with the severity of spermatogenic defects in subfertile
men. So far, lower inhibin B levels were reported in a limited
number of subfertile men, compared with fertile controls
(10). More recently, inhibin B was found to be correlated with
the sperm concentration in a study of 349 normal men (12)
and in a mixed group of 65 men with normal and impaired
spermatogenesis (13).
The aim of this study was to further investigate the clinical
value of inhibin B estimations in subfertile men and to cor-
relate inhibin B levels with clinical history, testicular volume,
testicular biopsy score, and sperm characteristics. Subse-
quently, we analyzed the additional value of inhibin B, com-
pared with that of FSH, with special emphasis on the dif-
ferentiation between normal and impaired spermatogenesis.
Subjects and Methods
Patients
The study comprised 218 consecutive patients that were referred to
our andrology outpatient clinic with fertility problems (age, 21–57 yr).
In the period September 1996 until October 1997, 235 new patients were
enrolled, of which 17 were excluded from further study on the basis of
medication (n 5 7; androgens or anti-estrogens), unilateral castration
(n 5 4), hypogonadotropic hypogonadism (n 5 3), systemic disease (n 5
1; renal failure), or chromosome translocation (n 5 2).
Infertility of the couple was defined as a duration of infertility of more
than 1 yr. Patients were subjected to a thorough clinical evaluation
according to the WHO Manual for the Standardized Investigation and
Diagnosis of the Infertile Couple (15). Patients were diagnosed with
normospermia (n 5 49; $20 million sperm/mL), idiopathic moderate
oligozoospermia (n 5 69; 5–20 million sperm/mL), idiopathic severe
oligozoospermia (n 5 58; .0 and ,5 million sperm/mL), idiopathic
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azoospermia (n 5 15), obstructive azoospermia (n 5 6, normal FSH,
normal testicular size, and Johnsen score . 8; in 3 of these men, con-
genital absence of the vas deferens was diagnosed with ultrasonogra-
phy), history of cryptorchidism (n 5 17, accompanied by oligozoosper-
mia), or Klinefelter’s syndrome (n 5 4).
Hormone analyses
Serum samples were stored for a period of 1 day to maximal 5 weeks
at 220 C before analysis. Inhibin B was measured using kits purchased
from Serotec Limited, Oxford, UK (16). The within-assay coefficient of
variance (CV) was less than 9%, and the between-assay CV was less than
15%. The lowest detectable inhibin B concentration was 5 pg/mL (based
on the mean value of the blanks 1 2 sd). A value of 2.5 pg/mL (the mean
of the undetectable range) was assigned to test results below 5 pg/mL.
Serum FSH and LH were determined with the Amerlite FSH and LH
assays (Orange-Clinical Diagnostics, Amersham, UK). Within-assay and
between-assay CVs are less than 3, less than 8% and less than 5, less than
15% for FSH and LH, respectively. Total serum testosterone was deter-
mined by RIA, as described earlier (17) (within- and between-assay CV:
less than 6 and less than 9%). Using the above assays, mean (sd) FSH,
LH, and testosterone levels in a group of normal men were 2.5 (1.3) IU/L,
3.6 (1.9) IU/L, and 17.6 (6.8) nmol/L (18). Per patient, all hormone
concentrations were analyzed in the same blood sample.
Semen analysis
Semen analyses were carried out according to the WHO Laboratory
Manual for the Examination of Human Semen and Semen-Cervical
Mucus Interaction (19). Per patient, the results of the two semen analyses
that were performed closest in time to the hormone analyses were
selected. Per patient, the average sperm count was calculated. The me-
dian time difference (semen analysis date 2 blood sampling date) was
22 days (10th and 90th percentiles: -23, 51.4 days). Semen samples were
obtained and assessed in 205 of the 218 patients.
Testicular evaluation
Testicular volume was estimated with the Prader orchidometer. Bi-
lateral biopsy specimens were available on 22 of the 218 patients. Tes-
ticular biopsies were performed to discriminate impaired spermatogen-
esis from excurrent duct obstruction as a cause for azoospermia or severe
oligozoospermia. Criteria for testicular biopsy were: azoospermia ac-
companied by a normal FSH level, or less than 5 million sperm/mL
ejaculate. Biopsy specimens were scored using the method described by
Johnsen (20), as modified by Aafjes et al. (21). Seminiferous tubule
cross-sections were rated with a score from 1 to 10, based on the most
advanced stage of spermatogenesis observed. The mean score of at least
50 tubules was calculated per biopsy, both for the left and right testis.
Tubules scored 10 for complete and abundant spermatogenesis with at
least 5 condensed spermatids; 8 when all stages of spermatogenesis were
present, but less than 5 condensed spermatids were seen; 7 when no
condensed spermatids, but at least 5 round spermatids were present; 6
when no condensed spermatids, and less than 5 round spermatids
present; 5 when no spermatids, but 5 or more spermatocytes present; 4
when no spermatids and less than 5 spermatocytes were present; 3 only
spermatogonia present; 2 for Sertoli cells only; and 1 for no cells in the
tubular section. It was previously shown that spontaneous pregnancy is
possible when a biopsy score of $8 is present, but highly unlikely below
a Johnsen score of 8 (21).
Statistical analysis
The FSH, LH, testosterone, and sperm count variables were trans-
formed logarithmically to achieve a normal distribution. Correlations
were calculated with Pearson’s method. Differences between patient
groups were tested with one-way ANOVA, followed by Fisher’s least-
significant difference method for pairwise comparisons.
The performance of inhibin B or FSH estimations in discriminating
between normal and impaired spermatogenesis (Johnsen score $ 8 or
,8) was described by receiver operating characteristic (ROC) statistics.
ROC curves were drawn by plotting the sensitivity against the false
positive rate (1-specificity) for varying cutoff levels of inhibin B and FSH.
A nondiscriminating test would follow the diagonal line of the figure,
whereas a 100% accurate so-called gold standard test would coincide
with the upper left corner of the box. By comparing the areas under the
curve (AUCs) for inhibin B and FSH, the diagnostic values of both
hormones were compared (22). AUCs were estimated with the Wilcoxon
statistic (23).
Independent variables predictive of the biopsy score were identified
with linear multiple regression analysis. Two-sided P values less than
0.05 were considered significant. Statistical analyses were carried out
with the SPSS 7.5 for Windows statistical software package.
Results
Inhibin B was detectable in all but 6 men, with a mean
concentration of 144.2 6 4.9 (sem) pg/mL. Subdivided by
diagnosis, the mean (sem) serum inhibin B concentrations
were 244.0 (31.6) for obstructive azoospermia, 181.9 (9.1) for
normospermia, 166.1 (7.3) for moderate oligozoospermia,
128.4 (8.8) for severe oligozoospermia, 52.0 (14.4) for idio-
pathic azoospermia, 7.3 (2.5) for Klinefelter’s syndrome, and
118.1 (18.3) pg/mL for patients with a history of cryptorchid-
ism (Fig. 1). Compared with the group with normospermia,
the mean serum inhibin B levels were significantly lower in
the groups with severe oligozoospermia, idiopathic
azoospermia, Klinefelter’s syndrome, and a history of cryp-
torchidism. The mean inhibin B level in patients with ob-
structive azoospermia, in which spermatogenesis may be
normal, was significantly higher, when compared with the
other groups.
Table 1 shows the correlations of inhibin B with param-
eters related to spermatogenesis. The inhibin B levels were
correlated with the total sperm count (r 5 0.54, P , 0.001; Fig.
2); patients with obstructive azoospermia were excluded
from this correlation and other correlations with the sperm
count. The inhibin B levels were also significantly correlated
with the total bilateral testicular volume (Fig. 3), the Johnsen
score (Fig. 4), and negatively with serum FSH (Fig. 5) and LH
levels. The correlation of inhibin B with LH was not signif-
FIG. 1. Serum inhibin B levels in subgroups of subfertile men. The
horizontal line per group indicates the mean level (*, the mean inhibin
B level was significantly lower, compared with normospermia, P ,
0.05; **, the mean inhibin B level in patients with obstructive
azoospermia was significantly higher, compared with other groups,
P # 0.01).
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icant if it was adjusted for the FSH level (r 5 0.03, P 5 0.63),
with which LH is closely correlated.
The accuracy for differentiating adequate (Johnsen score $
8) from impaired spermatogenesis (Johnsen score ,8), on the
basis of inhibin B and FSH levels, was estimated from the
area under the ROC curve (Fig. 6). The AUC was 0.95 (se:
0.07) for inhibin B and 0.80 (se: 0.12) for FSH. The areas under
the ROC curves for inhibin B and FSH were statistically
different (P 5 0.04). Depending on the desired sensitivity or
specificity of inhibin B or FSH, a cutoff level can be deduced
from the ROC curves. When the point on the curve closest to
the upper left corner of the box corresponding to 100% sen-
sitivity and 0% false positives (100% specificity) was selected,
TABLE 1. Correlations between Inhibin B, FSH, LH, testosterone (T), testicular volume (TV, sum of left and right testis), mean bilateral
Johnsen score, and sperm count are in italic, and number of patients (P value) are boldface.
Inhibin B FSH LH T TV Johnsenscore
Sperm
count
Inhibin B 20.78a 20.41a 0.20a 0.63a 0.76a 0.54a
FSH 218 (<0.001) 0.55a 20.17a 20.56a 20.64a 20.55a
LH 218 (<0.001) 218 (<0.001) 0.01 20.34a 20.35 20.32a
T 208 (<0.004) 208 (0.02) 208 (0.97) 0.18a 0.38 0.13
TV 166 (<0.001) 166 (<0.001) 166 (<0.001) 164 (0.02) 0.34 0.38a
Johnsen score 22 (<0.001) 22 (0.001) 22 (0.11) 21 (0.11) 20 (0.14) 0.53a
Sperm count 205 (<0.001) 205 (<0.001) 205 (<0.001) 202 (0.07) 156 (<0.001) 17 (0.03)
a Correlation coefficients are statistically significant.
FIG. 2. Serum inhibin B plotted against the total sperm count in 205
subfertile males (r 5 0.54, P , 0.001).
FIG. 3. Serum inhibin B levels plotted against the testicular volume
of 166 subfertile males (r 5 0.63, P , 0.001).
FIG. 4. Serum inhibin B plotted against the mean bilateral Johnsen
scores of 22 subfertile males (r 5 0.76, P , 0.001).
FIG. 5. Serum FSH concentration plotted against serum inhibin B in
218 subfertile males (r 5 20.78, P , 0.001).
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this resulted in cutoff levels of inhibin B less than 139 pg/mL
and FSH more than 4.9 IU/L to identify patients with im-
paired spermatogenesis. The sensitivity and specificity cor-
responding to these cutoffs were 83 and 90% for inhibin B,
and 75 and 80% for and FSH, respectively.
In addition, linear multiple regression was performed to
study whether hormonal variables could account for the
variation in the mean bilateral Johnsen score. The Johnsen
score was predicted from FSH and inhibin B, the variables
correlated with it in Table 1. Sperm count was not entered as
an independent variable, because an unrevealed (partial)
obstruction may bias the biopsy score vs. sperm count cor-
relation. The regression procedure indicated inhibin B as the
best predictor of the Johnsen score, explaining 58% of the
variance. In the resulting regression equation [Johnsen
score 5 4.78 1 (0.017 3 inhibin B) 1 (0.05 3 FSH)], the
coefficient for inhibin B was statistically significant (P 5
0.007), whereas FSH did not improve the regression model
(P 5 0.24).
Discussion
In this study, we demonstrate a significant correlation
between sperm concentration, sperm count, and testicular
volume on the one hand, and serum inhibin B levels on the
other. These results provide strong evidence that inhibin B is
an important marker of the competence of Sertoli cells and
spermatogenesis in the human, which is in accordance with
the few reports on inhibin B and quality of spermatogenesis
up to now (9, 10, 12, 13). In the first two studies, a lower
inhibin B concentration was noted in small groups of men
with azoospermia, testicular disorders, and infertility, as
compared with fertile controls. More recently, results of two
larger study populations became available, showing a sig-
nificant positive correlation of inhibin B with sperm concen-
tration in 349 normal men (12), and with sperm concentration
and testicular volume in 65 men with normal and impaired
spermatogenesis (13).
We now provide further evidence for the value of inhibin
B as a marker of spermatogenesis by the novel finding of a
statistically significant positive correlation with the most ac-
curate assessment of spermatogenesis in our setting, the tes-
ticular biopsy score. We compared the accuracy of FSH and
inhibin B levels to distinguish between patients with com-
petent and impaired spermatogenesis, based on the Johnsen
score. The area under the ROC curve, corresponding to the
accuracy of the diagnostic method, was significantly larger
for inhibin B. Multiple linear regression analysis also re-
vealed that FSH had no significant additional predictive
value for the Johnsen score above inhibin B.
The choice for a cutoff level for inhibin B or FSH to dis-
criminate competent from impaired spermatogenesis de-
pends on the priority of a high sensitivity or specificity. We
arbitrarily chose the cutoff level closest to the upper left
corner of the box. The resulting cutoff levels for inhibin B
(,139 pg/mL) and FSH (.4.9 IU/L) were surprisingly close
to the cutoff levels for these hormones based on control
populations. A lower normal limit for inhibin B has not been
defined, but it was 140.6 pg/mL (95% confidence interval,
140.6–225.7) for a group of 18 semen donors (9). We use 5.1
IU/L as the upper normal limit for FSH based on the mean
plus 2 sd [2.5 1 (2 3 1.3)] in a population of normal men (17).
The present data show significant differences in mean
inhibin B levels between diagnostic subgroups. The inhibin
B levels were significantly lower in patients with a spermat-
ogenic defect, as compared with the group with normosper-
mia. Patients with obstruction as the sole identified cause for
azoospermia had normal inhibin B levels, which were sig-
nificantly higher, compared with other subgroups. With the
aspecific heterologous assay for inhibin, no differences in
inhibin levels between comparable subgroups were found
(7).
A further advantage of inhibin B measurement is that it
reflects the function of the total testicular tissue, whereas a
biopsy may not be representative for the entire testis. Mul-
tiple biopsies, which are nowadays performed for testicular
sperm extraction, often show a large variation in the com-
pleteness of spermatogenesis (24). This heterogeneity of sper-
matogenesis is even more conspicuous in patients with im-
paired spermatogenesis, where sections with complete
spermatogenesis may be found among others with germinal
cell aplasia, referred to as focal spermatogenesis (25). It has
to be established whether inhibin B levels can demonstrate
the presence of focal spermatogenesis and, in this way, could
reduce the need for invasive testicular biopsies. It is not
unlikely that, in many cases, the area of spermatogenesis is
too small to substantially increase serum inhibin B levels.
FSH was regarded the most important endocrine marker
for testicular function until now (26). The diagnostic value of
inhibin B for spermatogenetic disorders seems to be better.
This may be explained by the fact that inhibin is a direct
product of the seminiferous tubules, and that its secretion is
stimulated by the presence of advanced stages of spermat-
ogenesis (27). In contrast, FSH levels are also affected by
GnRH, estradiol, and testosterone.
In conclusion, we have confirmed the role of inhibin B in
FSH regulation, and we have found a strong correlation of
inhibin B levels with spermatogenesis. Our results provide
further and novel evidence that inhibin B is the best known
endocrine marker for spermatogenesis. Inhibin B estimation
FIG. 6. ROCs of inhibin B and FSH for discriminating normal and
disturbed spermatogenesis. INHB, Inhibin B.
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may prove an alternative for testicular biopsy in the differ-
entiation between normal and impaired spermatogenesis.
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